论文部分内容阅读
目的:探索并讨论孟鲁司特钠在儿科哮喘治疗中的临床疗效分析。方法:选择2012年2月-2014年2月期间在吴川市人民医院治疗的80例儿科哮喘患者作为研究对象,利用随机分组方式分为观察组和对照组,各40例患者,其对照组为哮喘患者进行常规的治疗,观察组是在常规治疗上再使用适量的孟鲁司特钠,比较两组治疗效果。观察两组治疗4周后白天与夜晚哮喘的发作次数以及治疗8周后白天与夜晚哮喘的发作次数,将两组进行相应比较;观察并比较从治疗之后的3个月哮喘患者体内积累的糖皮质激素和速效β2受体激动剂的总量。结果:观察组4周后白天与夜晚哮喘的发作次数与8周后再观察白天与夜晚哮喘的发作次数都少于对照组(P<0.05),并且观察者3个月哮喘患者体内积累的糖皮质激素和速效β2受体激动剂的总量也比对照组要少(P<0.05),观察组的总有效率(92.5%)高于对照组(65.0%)(P<0.05)。结论:孟鲁司特钠在儿科哮喘治疗中的临床治疗效果良好,能有效减少白天与夜晚哮喘的发作次数与降低哮喘患者体内积累的糖皮质激素和速效β2受体激动剂的总量,而且极少不良反应。
Objective: To explore and discuss the clinical efficacy of montelukast in the treatment of pediatric asthma. Methods: A total of 80 pediatric patients with asthma treated in Wuchuan People’s Hospital from February 2012 to February 2014 were selected as study subjects and randomly divided into observation group and control group, 40 cases in each group. The control group was Asthma patients were treated routinely. The observation group was treated with appropriate amount of montelukast sodium on conventional therapy, and the treatment effect was compared between the two groups. The number of asthma attacks during the day and night after 4 weeks of treatment and the number of asthma attacks during the day and night after 8 weeks of treatment were observed. The two groups were compared accordingly. The accumulation of sugar in the asthma patients after 3 months of treatment was observed and compared The total amount of corticosteroids and fast acting beta 2 receptor agonists. Results: The number of asthma attacks in day and night 4 weeks after the observation group and the number of asthma attacks in day and night after 8 weeks were all less than those in the control group (P <0.05), and the accumulation of sugar The total amount of corticosteroids and fast-acting β2 agonists was also lower than that of the control group (P <0.05). The total effective rate (92.5%) in the observation group was higher than that of the control group (65.0%) (P <0.05). CONCLUSIONS: Montelukast is clinically effective in the treatment of pediatric asthma and is effective in reducing the number of asthma attacks during the day and night, reducing the total amount of glucocorticoid and fast acting beta 2 receptor agonist accumulated in asthmatic patients, and Very few adverse reactions.